About Me

As a gastroenterologist and hepatologist at The Ohio State University Wexner Medical Center, I see patients in clinic and perform endoscopic procedures. I enjoy working at OSU because it provides comprehensive support for patient care and a robust research environment. This makes it possible for me to provide the most appropriate and individualized care to my patients. In addition, patients also have the opportunity to receive the latest treatments through clinical trials.

My clinical focus is Non-Alcoholic Fatty Liver Disease (NAFLD), which affects about one-quarter of people worldwide. Patients with obesity and type 2 diabetes are at particularly high risk for disease progression (NASH), which often leads to poor health outcomes. Therefore, it is important to raise public awareness of NAFLD and intervene at early stages of the disease. Optimized care for patients with NAFLD requires teamwork among multi-specialty physicians, medical counselors, patients, and their family members. I feel fortunate to be a part of this team and happy to make such a positive impact on my patients’ lives.

When I am not working, I enjoy spending time with family, dancing, and traveling.

Learn more about receiving a tailored approach to treating fatty liver disease at the Ohio State Wexner Medical Center: https://wexnermedical.osu.edu/liver-diseases/fatty-liver-disease

Highlights

• CURRENTLY AVAILABLE CLINICAL TRIALS ON NAFLD AS A PRINCIPLE INVESTIGATOR
• ESSENCE study - The effect of semaglutide in subjects with non-cirrhotic NASH (phase 3). Status: actively enrolling.
• Study by Galectin - A seamless, adaptive, phase 2b/3, double-blind, randomized, placebo-controlled, multicenter, international study evaluating the efficacy and safety of belapectin for the prevention of esophageal varices in NASH cirrhosis. Status: actively enrolling.
• REVERSE study - A phase 3, double-blind, randomized, placebo-controlled, multicenter study to evaluate the efficacy and safety of obeticholic acid in subjects with compensated cirrhosis due to non-alcoholic steatohepatitis (NASH). Status: completed enrollment.
• AURORA study - A phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate efficacy and safety of cenicriviroc for the treatment of liver fibrosis in adults with NASH. Status: early termination (due to lack of significant benefits).
• For more information on these clinical trials, contact Anitha Guduri (Anitha.guduri@osumc.edu) or Gabrielle Volk (gabrielle.volk@osumc.edu).

Additional Languages I Speak

• Mandarin

Procedures and Conditions I Treat

• Hepatitis, Viral, Human
• Gastroesophageal Reflux
• Irritable Bowel Syndrome
• Inflammatory Bowel Diseases
• Liver Diseases
• Endoscopy, Gastrointestinal
• Capsule Endoscopy
• Gastrointestinal Hemorrhage
• Constipation
• Digestive System Diseases
• Fatty Liver
• Neurosecretory Systems
• Hepatitis
• Liver Cirrhosis
• Colonoscopy
• Diarrhea
• Gastroenteritis
• Peptic Ulcer
• Celiac Disease
• Gastroscopy

My Videos